NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS CONTINUED 4. OPERATING SEGMENTS Identification of reportable operating segments The segment reporting reflects the way information is reported internally to the chief operating decision maker. The Board of the Group has been identified as the chief operating decision maker. The Board assesses the financial performance and position of the group and makes strategic decisions. The Group has two reportable operating segments, commercial products and research and development. Reportable segment Principal activities Commercial products Milestone and royalty revenue from licence of intellectual property. Research & development Development of pharmaceutical products for the treatment of neurodevelopmental disorders. Commercial products Research & Development Corporate Total Dec-24 $’000 Dec-23 $’000 Dec-24 $’000 Dec-23 $’000 Dec-24 $’000 Dec-23 $’000 Dec-24 $’000 Dec-23 $’000 Revenue 213,243 231,925 – – – – 213,243 231,925 Research and development costs – (66) (32,970) (26,685) – – (32,970) (26,751) Finance income – – – – 11,014 5,687 11,014 5,687 Other income – – – – 2 17 2 17 Other expenses – – – – (4,701) (5,946) (4,701) (5,946) Net foreign currency (loss)/gain – – – – (7,235) 2,434 (7,235) 2,434 Gain/(loss) on financial derivatives 3,587 (2,226) 3,587 (2,226) Profit before income tax 213,243 231,859 (32,970) (26,685) 2,667 (34) 182,940 205,140 Income tax expense – – – – (40,897) (48,059) (40,897) (48,059) Profit after income tax 213,243 231,859 (32,970) (26,685) (38,230) (48,093) 142,043 157,081 Other comprehensive income – – – – 24,198 (10) 24,198 (10) Total comprehensive income 213,243 231,859 (32,970) (26,685) (14,032) (48,103) 166,241 157,071 All revenue from licences of intellectual property is from Acadia Pharmaceuticals Inc. (Acadia) and is from the United States. Assets and liabilities are not allocated to segments and are therefore not reported. Neuren Pharmaceuticals Limited Annual Report 2024 33
RkJQdWJsaXNoZXIy MjE2NDg3